The global contraceptive market size is expected to reach USD 45.1 billion by 2030, registering a CAGR of 6.06% from 2023 to 2030, based on a new report by Grand View Research, Inc. The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the introduction of new products exhibiting improved efficacy is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth. The government spending on contraceptives is growing rapidly.
This is expected to drive the growth of the market over the forecast period. According to the Family Planning 2020 Women at the Center report, Australia provided USD 22.2 million in bilateral family planning funding for the 2017 - 2018 fiscal year. The U.S. provided USD 630.6, the U.K. provided USD 292.2, Canada provided USD 81.8, and Germany provided USD 51.3 in bilateral family planning funding for the 2017 - 2018 fiscal year. The COVID-19 pandemic has negatively impacted the global industry. The negative impact can be attributed to the supply-chain disruption, and decline in demand for sexual and reproductive health services globally.
As per the Impact of COVID-19 on access to contraceptives in the LAC region by UNFPA, in Brazil, around 195,658 public-sector users were unable to access contraceptives with moderate disruption for six months during the pandemic, and around 97,829 public-sector users were unable to access contraceptives with low disruptions for three months, and around 391,316 public-sector users were unable to access contraceptives with high disruptions for twelve months. The industry is highly competitive with the presence of many major players. Companies are majorly investing in R&D and are adopting other strategies including M&As and expanding product pipelines. For instance, in April 2021, FDA approved a combination tablet of estetrol and drospirenone
Request a free sample copy or view the report summary: Contraceptives Market Report
The contraceptive device segment held the largest market share 65.66% in 2022 owing to higher success rates and the single-use nature of the devices
Based on products, the contraceptive drugs segment is expected to witness the fastest CAGR 7.12% during the forecast period owing to the affordability, easy accessibility, and significant success rates pertaining to these medications
North America accounted for the largest revenue share in 2021. The presence of sophisticated healthcare infrastructure, high user awareness levels, and easy product availability are key factors responsible for the region’s high share
Asia Pacific is expected to witness substantial growth during the forecast period owing to rapidly rising population levels and the consequent rise in demand for contraception
The presence of government initiatives in countries, such as India, China, Sri Lanka, Pakistan, and Bangladesh, aimed at slowing down population growth and the prevalence of STDs are expected to promote market growth
Grand View Research has segmented the global contraceptive market based on product and region:
Contraceptive Product Outlook (Revenue, USD Million, 2017 - 2030)
Contraceptive Drugs
Contraceptive Pills
Patch
Injectables
Contraceptive Devices
Condoms
Male Condoms
Female Condoms
Subdermal Implants
IUDs
Copper IUDs
Hormonal IUDs
Vaginal Rings
Diaphragm
Contraceptive Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Mexico
Brazil
Argentina
Middle East & Africa (MEA)
South Africa
Saudi Arabia
UAE
List of Key Players in Contraceptive Market
Bayer AG
China Resources Zizhu Pharmaceutical Co., Ltd. (CR Zizhu)
Cupid Limited
Helm AG
Church & Dwight
Organon Group of Companies
Pfizer Inc.
Viatris (Mylan)
Abbvie, Inc.
Afaxys, Inc.
Agile Therapeutics
Janssen Pharmaceuticals, Inc.
Veru, Inc.
"The quality of research they have done for us has been excellent..."